Blair William & CO Nu Cana PLC Transaction History

Blair William & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$2.7 - $5.04 $36,315 - $67,788	-13,450 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$4.38 - $7.0 $21,900 - $35,000	-5,000 Reduced 27.1%	13,450 $67,000
Q4 2020 Feb 09, 2021	SELL	$4.4 - $5.59 $77,440 - $98,384	-17,600 Reduced 48.82%	18,450 $83,000
Q3 2020 Nov 06, 2020	BUY	$4.57 - $6.48 $53,012 - $75,168	11,600 Added 47.44%	36,050 $186,000
Q2 2020 Aug 12, 2020	BUY	$4.87 - $7.37 $23,497 - $35,560	4,825 Added 24.59%	24,450 $132,000
Q1 2020 May 11, 2020	BUY	$4.02 - $9.05 $12,059 - $27,150	3,000 Added 18.05%	19,625 $114,000
Q4 2019 Feb 13, 2020	SELL	$5.55 - $8.48 $79,920 - $122,112	-14,400 Reduced 46.41%	16,625 $101,000
Q3 2019 Nov 12, 2019	BUY	$6.95 - $10.71 $215,623 - $332,277	31,025 New	31,025 $225,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.